arrow
H

Helai P. Mohammad

sk life sciences laboratories
H指数:30
被引数:5,357

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Overcoming CK1α liability in the discovery of a series of isoIndolinone Glutarimides as selective IKZF2 molecular glue degraders

在发现一系列异吲哚啉酮戊二酰亚胺作为选择性IKZF2分子胶降解剂时克服CK1α 责任

2025-05-150
PRE
Discovery and Characterization of PVTX-321 as a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2-Breast Cancer

PVTX-321的发现与表征:一种强效且口服生物利用度高的雌激素受体降解剂,用于ER+/HER2-乳腺癌

2025-05-140
PRE
The selective IKZF2 molecular glue degrader, PVTX-405, counters Treg immune suppression,shows significant tumor growth delay as single agent and synergistic response with immune checkpoint therapies (ICTs)
2024-03-220
PRE
Predictive wild-type RAS/BRAF and pharmacogenetic biomarkers drive selection of metastatic colorectal cancer patients fit for intensive first-line FIr-C/FOx-C schedule adding cetuximab to triplet chemotherapy
2023-12-010
PRE
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
2021-09-27141
PREAI
Discovery of Isoxazole Amides as Potent and Selective SMYD3 Inhibitors
2019-12-2712
OAAI
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML
2019-07-0137
OAAI
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
2019-06-20124
OAAI
Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma
2019-01-1872
OAAI